Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (23705)	5/21/2007 1:40:56 PM
From: Biomaven	Read Replies (1) of 52153

<Xopenex> The issue there is that Sepracor has never really shown a clear advantage over albuterol other than less frequent dosing and a very marginal reduction in side effects. I personally believe it is a better drug for long-term use - certainly animal studies point to that being the case, but that is a long way from getting something in the label to that effect. They've just never run the large, long-term trials needed to validate that Xopenex is indeed a better drug. I don't myself understand the bureaucratic legalities of the CMS decision. I have a few SEPR shares left, mostly because I couldn't bring myself to sell them given a basis near $6.00. The new guy (Adams) is good - too bad he wasn't there a few years ago. Their R&D focus in the past few years on CNS drugs at the expense of respiratory was a big mistake in my view. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next